

3 avenue des Tropiques  
Z.A. de Courtabœuf  
91 940 LES ULIS  
Tél : + 33 (0) 1 69 82 70 10  
Fax : +33 (0) 1 69 07 19 03

# Carbon Reduction Plan

Supplier name: LFB Biomedicaments.....

Publication date: 04/02/2026

## Commitment to achieving Net Zero

LFB Biomedicaments is committed to achieving Net Zero emissions by 2050

## Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

<b>Baseline Year: reporting of 2022</b>	
<b>Additional Details relating to the Baseline Emissions calculations.</b>	
<b>Baseline year emissions: 2022 - This is the first year in which LFB has carried out the most complete carbon assessment based on its constant methodology /scope improvement approach and the GHG Protocol Corporate Accounting and Reporting Standard methodology.</b>	
EMISSIONS	<b>TOTAL (tCO<sub>2</sub>e)</b>
Scope 1	12 304
Scope 2	2 852
Scope 3 (Included Sources)	104 761
<b>Total Emissions</b>	<b>119 916</b>

— Siège social —

LFB BIOMÉDICAMENTS S.A.

S.A. au capital de 150 000 000 Euros – 491 371 167 RCS Evry  
3 avenue des Tropiques – ZA de Courtabœuf – 91940 LES ULIS

## Current Emissions Reporting

<b>Reporting Year: 2024</b>	
<b>EMISSIONS</b>	<b>TOTAL (tCO<sub>2</sub>e)</b>
<b>Scope 1</b>	15 955
<b>Scope 2</b>	4 129
<b>Scope 3 (Included Sources)</b>	84 301
<b>Total Emissions</b>	104 385

### Emissions reduction target

LFB uses the GHG Protocol Corporate Accounting and Reporting Standard methodology to calculate its carbon footprint. Since 2017, the company has published its Scopes 1, 2 and 3.

During the reporting year, a rebaselining exercise of the company's carbon footprint was carried out, including a more comprehensive accounting of input materials, a reassessment of the emission factor associated with plasma, which represents LFB's main input, and an improved quantification of emissions related to the end-of-life of products sold by LFB.

The company has defined decarbonization targets for Scopes 1, 2 and 3. LFB has clear goals established in its 2030 Agenda, leading to a **43%** reduction in our carbon trajectory to 2022.

### Carbon Reduction Projects

#### Completed Carbon Reduction Initiatives

The decarbonization plan for scope 1 and 2 was developed based on the results of a strong and detailed energy audit of LFB Biomédicaments' industrial sites. The 28 projects that make up the plan, the progress of which is monitored monthly by the Executive Committee in terms of timelines, as well as associated means and resources.

The preparation for ISO 50001 certification by 2026 will sustainably support the reduction of scopes 1 and 2 and the improvement of LFB's energy efficiency.

---

Siège social

LFB BIOMÉDICAMENTS S.A.

S.A. au capital de 150 000 000 Euros – 491 371 167 RCS Evry  
3 avenue des Tropiques – ZA de Courtabœuf – 91940 LES ULIS

Regarding scope 3, LFB has continued in 2025 the actions previously implemented to contribute to the reduction of the associated carbon emissions. These actions include the application of a Travel Policy aimed at minimizing carbon emissions related to business travel and employee commuting, the inclusion of the right to telecommute (up to two days per week), and the ongoing increase in the proportion of electric and hybrid vehicles within the company car fleet.

In addition, LFB has strengthened its approach to scope 3 decarbonization through the launch of structuring projects. These include the internalization of the annual measurement of the company's carbon emissions in order to improve monitoring and governance of LFB's decarbonization trajectory; the initiation of Life Cycle Assessment (LCA) calculations for selected strategic LFB products, with the long-term objective of integrating eco-design principles into their development; and the optimization of upstream and downstream logistics flows across the medicinal product production phases.

Additional actions underway also include the implementation of a responsible purchasing policy designed to leverage the decarbonization actions undertaken by LFB's suppliers, as well as the commissioning of a dedicated treatment unit for infectious healthcare waste (DASRI), enabling the establishment a circular economy loop through the reuse of recycled materials.

## Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard<sup>1</sup> and uses the appropriate Government emission conversion factors for greenhouse gas company reporting<sup>2</sup>.


Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard<sup>3</sup>.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

**Signed on behalf of the Supplier:**

Date: .....

26.01.26



<sup>1</sup><https://ghgprotocol.org/corporate-standard>

<sup>2</sup><https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

<sup>3</sup><https://ghgprotocol.org/standards/scope-3-standard>

---

Siège social

LFB BIOMÉDICAMENTS S.A.

S.A. au capital de 150 000 000 Euros – 491 371 167 RCS Evry

3 avenue des Tropiques – ZA de Courtabœuf – 91940 LES ULIS